Guest Editors
Sanghee Lee
University of California San Diego
<p>Dr. Sanghee Lee received her PhD from the Department of Urology and Cellular and Molecular Biology Program at the University of Wisconsin-Madison in 2015. Her thesis mentor was Dr. Wade Bushman and she described neural cross-talk between the bladder and prostate as well as prostate inflammation-induced functional changes in urinary bladder of adult mice. As a postdoctoral fellow, Dr. Lee studied neurogenic bladder dysfunction in a murine model of multiple sclerosis in the laboratory of Dr. Anna Malykhina at the University of Colorado Anschutz Medical Campus. In 2017, Dr. Lee joined the University of California San Diego (UCSD) as the first Neuro-Urology Fellow with a joint appointment in the UCSD Dept. of Urology and at Rady Children’s Hospital San Diego. Her research advisory committee members are Dr. Christina Jamieson (PI), Dr. George Chiang, Dr. Yahir Santiago-Lastra, Dr. Todd Coleman and Dr. Tony Yaksh. Her current research interests include the mechanisms of metastasis and pain in bone metastatic prostate cancer. </p>
Christina Jamieson
University of California San Diego
<p>Dr. Jamieson is a translational scientist in Urologic Oncology, in the Department of Urology, University of California, San Diego (UCSD). She investigates the causes of bone metastasis and has established new patient sample derived models to test new therapies and offer hope to patients with advanced, castration resistant prostate cancer. She obtained her PhD in Molecular Immunology at Brandeis University with Dr. Ranjan Sen and showed that T cell receptor (TCR) stimulation itself induced NF-kB activation and NF-AT. Dr. Jamieson moved to the University of California, San Francisco (UCSF) for her post-doctoral fellowship, first with Dr. Dan R. Littman and then with Dr. Keith R. Yamamoto. She uncovered mechanisms of signaling crosstalk between TCR and glucocorticoids that regulate the survival of T cell progenitors, thus shaping the immune repertoire. These pathways can also be dysregulated in steroid hormone-driven cancers. Dr. Jamieson began as an Assistant Professor in the Depts. Of Urology and Human Genetics at UCLA to investigate mechanisms of resistance to steroid hormone-based therapy in cancer then moved to UCSD to focus on how to overcome therapy-resistance in bone metastatic prostate cancer using patient samples-based models and new therapies.</p>
Collection Overview
Organoids are three-dimensional (3D) ex vivo cellular structures that are believed to recapitulate and maintain the in vivo conditions of cellular viability and responsiveness to therapeutic drugs. Matrigel or collagen have been utilized as an extracellular matrix to enable patient-derived cells to form 3D/organoids including cyst-like structures and spheroids. 3D cultured organoids are considered to be excellent models to understand the mechanisms of tumorigenesis and to determine the effects of anticancer agents. Therefore, methods have been developed for a range of cancers such as brain, breast, lung and prostate, among others. Prostate, however, is somewhat unique in that current methods for culturing organoids have a lower success rate than for other cancers. Difficulty in establishing prostate organoid cultures may be driven in part by tumorigenic heterogeneity. Most prostate organoids are derived from patient-derived xenografts (PDXs) and are genomically representative of the patient’s prostate cancer. Therefore, PDX organoids models are invaluable for studying down-stream signaling of target molecules and the effects of anti-cancer agent treatment. Several groups have developed modified protocols that are optimized for their experimental objectives. The goal of this collection is to (1) provide several examples of optimized culture condition for patient-derived prostate cancer 3D organoids, (2) introduce follow-up methodologies for single cell methods such as RNA-FISH and flow cytometry, (3) share meticulous details of immunohistochemistry (IHC)/ immunofluorescent (IF) technique specific for organoids and, (4) differential criteria to determine the effects of drug treatment on organoids.
Articles
Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
0 Views
•
Cited by 10
•
2019
•
Preston D. Crowell*1, Jenna M. Giafaglione*1, Takao Hashimoto2, Johnny A. Diaz2, Andrew S. Goldstein2,3,4,5,6
1Molecular Biology Interdepartmental Program, University of California, Los Angeles, 2Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, 3Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, 4Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, 5Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 6Molecular Biology Institute, University of California, Los Angeles
Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts
0 Views
•
Cited by 16
•
2020
•
Sanghee Lee1,2, Danielle N. Burner1,2, Theresa R. Mendoza1,2, Michelle T. Muldong1,2, Catalina Arreola1,2, Christina N. Wu2,3, Nicholas A. Cacalano4, Anna A. Kulidjian2,5, Christopher J. Kane1,2, Christina A. M. Jamieson1,2
1Department of Urology, University of California, San Diego, 2Moores Cancer Center, University of California, San Diego, 3Department of Medicine, University of California, San Diego, 4Department of Radiation Oncology, University of California, Los Angeles, 5Department of Orthopedic Surgery, University of California, San Diego
Isolation of Stem-like Cells from 3-Dimensional Spheroid Cultures
0 Views
•
Cited by 7
•
2019
•